Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sucralfate
Drug ID BADD_D02081
Description Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655]. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Indications and Usage For the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment of gastric ulcer.
Marketing Status Prescription
ATC Code A02BX02
DrugBank ID DB00364
KEGG ID C07314
MeSH ID D013392
PubChem ID 121494085
TTD Drug ID D06ULU
NDC Product Code 71052-009; 81646-101; 71610-541; 29033-003; 51079-753; 51552-0039; 72189-234; 42291-757; 80425-0188; 66689-790; 59762-0401; 69984-001; 55603-805; 55512-0019; 55603-215; 55154-4379; 55512-0009; 55154-5778; 53002-4930; 55512-0002; 55512-0020; 66039-946; 55154-8133; 55603-611; 17856-0170; 50090-5287; 0093-2210; 58914-170; 68071-1749; 0121-0747; 63629-9153; 68788-8946; 63629-1307; 63629-9152; 50090-0582; 55603-225; 70518-0775; 58914-172; 69339-148; 10695-091; 62991-1148; 63739-943; 80425-0091; 0395-8155; 55512-0021; 71610-017; 68094-043; 66267-596; 66689-305; 38779-0318; 58914-171; 0615-4517; 49452-7401; 0254-1011
Synonyms Sucralfate | Aluminum Sucrose Sulfate | Sulfate, Aluminum Sucrose | Basic Aluminum Sucrose Sulfate | Ulsanic | Ulcerban | Ulcogant | Antepsin | Carafate
Chemical Information
Molecular Formula C12H54Al9O55S8
CAS Registry Number 54182-58-0
SMILES C(C1C(C(C(C(O1)OC2(C(C(C(O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS (=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O. O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.0030.001621%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000540%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Back pain15.03.04.005--
Bezoar07.11.01.008--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000811%Not Available
Calcinosis08.03.04.0020.000540%Not Available
Cerebral artery embolism24.01.04.001; 17.08.01.001--Not Available
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.0020.000540%Not Available
Constipation07.02.02.001--
Death08.04.01.001--
Diarrhoea07.02.01.0010.001081%
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Drug hypersensitivity10.01.01.0010.001081%Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.0010.000540%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.000811%
Flatulence07.01.04.002--
Gastrooesophageal reflux disease07.02.02.0030.000811%
Headache17.14.01.001--
Hypersensitivity10.01.03.0030.002161%
Impaired gastric emptying07.02.02.004--
Insomnia19.02.01.002; 17.15.03.002--
Laryngospasm22.04.02.002--
Malaise08.01.01.0030.000540%
Nausea07.01.07.001--
Pneumonia22.07.01.003; 11.01.09.0030.002161%Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages